Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLANET: Adjuvant pembrolizumab in early-stage triple-negative breast cancer with residual disease
2025-524229-41-00Phase 3Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in triple-negative breast cancer (TNBC) comparing Pembrolizumab + standard-of-care adjuvant with Standard-of-care adjuvant alone (2 arms). Primary endpoint: Invasive disease-free survival. Planned start Apr 2026; status: authorised.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2025-524229-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524229-41-00.